Bristol-myers Squibb Compnay

Alexandre L'Heureux

Patrick Y S Lam

Rejean Ruel

Yong-Jin Wu

Carl Thibeault

Jennifer X Qiao

Tammy C Wang

Zulan Pi

Huan He

Li-Qiang Sun

James Clifford Sutton

Jacques Y Roberge

Charles G Clark

Timur Gungor

Timothy F Herpin

Hannguang J Chao

Robert P Rehfuss

Carl Thibault

Huji Tuerdi

Gilles Bouthillier

Yalei Liu

Dora M Schnur

R Michael Lawrence

Piyasena Hewawasam

Wu Yang

John E Lloyd

Rajeev S Bhide

Yufeng Wang

Jie Chen

George O Tora

Carol Hui Hu

Michael S Bowsher

Gene G Kinney

Pierre Dextraze

Jean-Paul Daris

Steven Dworetzky

Sheldon Hiebert

Li-Quang Sun

Michael R Lawrence

Ruel Rejean

The present invention provides compounds of Formula (I): Formula (I) as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of P2Yreceptor which may be used medicaments. 

[object Object]

The present invention provides novel heteroaryl compounds and analogues thereof, which are selective inhibitors of the human P2Yreceptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Yreceptor activity.

The present invention provides novel pyridyl or phenyl ureas and analogues thereof, which are selective inhibitors of the human P2Yreceptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Yreceptor activity.

The present invention provides novel arylcyclopropylcarboxylic amides and related derivatives having the general Formula I wherein R, R, R, R, R, R, Rand Rare as defined in the specification, or a nontoxic pharmaceutically acceptable salt, solvate or hydrate thereof which are openers or activators of KCNQ potassium channels. The present invention also provides pharmaceutical compositions comprising said arylcyclopropylcarboxylic amides and to the method of treatment of disorders sensitive to KCNQ potassium channel opening activity such as migraine or a migraine attack, bipolar disorders, epilepsy, acute and chronic pain and anxiety.

Arylcyclopropylcarboxylic amides as potassium channel openers

The present invention provides novel 3-heterocyclic benzylamides and related derivatives having the general Formula I wherein R, R, R, R, R, R, A and Het are as defined in the specification, or a nontoxic pharmaceutically acceptable salt, solvate or hydrate thereof which are openers or activators of KCNQ potassium channels. The present invention also provides pharmaceutical compositions comprising said novel 3-heterocyclic benzylamides and to the method of treatment of disorders sensitive to KCNQ potassium channel opening activity such as migraine or a migraine attack, bipolar disorders, epilepsy, acute and chronic pain and anxiety.

3-Heterocyclic benzylamide derivatives as potassium channel openers

The present invention provides novel aryl hydroxyethyl amides and related derivatives having the general Formula I wherein R, R, R, R, R, R, Rand A are as defined in the specification, or a nontoxic pharmaceutically acceptable salt, solvate or hydrate thereof which are openers or activators of KCNQ potassium channels. The present invention also provides pharmaceutical compositions comprising said aryl hydroxyethyl amides and to the method of treatment of disorders sensitive to KCNQ potassium channel opening activity such as migraine or a migraine attack, bipolar disorders, epilepsy, acute and chronic pain and anxiety.

1-aryl-2-hydroxyethyl amides as potassium channel openers

The present invention provides compounds of formula I,and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

Azaindole kinase inhibitors

Cinnamide derivatives as KCNQ potassium channel modulators

Growing community of inventors

Ste-Julie, Canada

Alexandre L'Heureux